Redox and microglia in the pathophysiology of schizophrenia

Takahiro A. Kato, Fuminori Hyodo, Mayumi Yamato, Hideo Utsumi, Shigenobu Kanba

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Altered antioxidant status has been implicated in schizophrenia. Microglia are major sources of free radicals such as superoxide in the brain, and play crucial roles in various brain diseases. Recent postmortem and imaging studies have in-dicated microglial activation in the brain of schizophrenia patients. Animal models that express some phenotypes of schizophrenia have revealed the underlying microglial pathology. In addition, minocycline, an antibiotic and the best known inhibitor of microglial activation, has therapeutic e‹cacy in schizophrenia. We have recently revealed that vari- ous antipsychotics directly affect microglia via proin‰ammatory reactions such as oxidative stress, by in vitro studies using rodent microglial cells. Based on these ˆndings, we have suggested that microglia are crucial players in the brain in schizophrenia, and modulating microglia may be a novel therapeutic target. In this review paper, we introduce our hypothesis based on the above evidence. The technique of in vivo molecular redox imaging is expected to be a powerful tool to clarify this hypothesis.

Original languageEnglish
Pages (from-to)739-743
Number of pages5
JournalYakugaku Zasshi
Volume135
Issue number5
Publication statusPublished - Jan 1 2015

Fingerprint

Microglia
Oxidation-Reduction
Schizophrenia
Brain
Minocycline
Molecular Imaging
Brain Diseases
Superoxides
Antipsychotic Agents
Free Radicals
Rodentia
Oxidative Stress
Animal Models
Antioxidants
Pathology
Anti-Bacterial Agents
Phenotype
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

Kato, T. A., Hyodo, F., Yamato, M., Utsumi, H., & Kanba, S. (2015). Redox and microglia in the pathophysiology of schizophrenia. Yakugaku Zasshi, 135(5), 739-743.

Redox and microglia in the pathophysiology of schizophrenia. / Kato, Takahiro A.; Hyodo, Fuminori; Yamato, Mayumi; Utsumi, Hideo; Kanba, Shigenobu.

In: Yakugaku Zasshi, Vol. 135, No. 5, 01.01.2015, p. 739-743.

Research output: Contribution to journalArticle

Kato, TA, Hyodo, F, Yamato, M, Utsumi, H & Kanba, S 2015, 'Redox and microglia in the pathophysiology of schizophrenia', Yakugaku Zasshi, vol. 135, no. 5, pp. 739-743.
Kato TA, Hyodo F, Yamato M, Utsumi H, Kanba S. Redox and microglia in the pathophysiology of schizophrenia. Yakugaku Zasshi. 2015 Jan 1;135(5):739-743.
Kato, Takahiro A. ; Hyodo, Fuminori ; Yamato, Mayumi ; Utsumi, Hideo ; Kanba, Shigenobu. / Redox and microglia in the pathophysiology of schizophrenia. In: Yakugaku Zasshi. 2015 ; Vol. 135, No. 5. pp. 739-743.
@article{207e9320c8804c348114ddad81a70856,
title = "Redox and microglia in the pathophysiology of schizophrenia",
abstract = "Altered antioxidant status has been implicated in schizophrenia. Microglia are major sources of free radicals such as superoxide in the brain, and play crucial roles in various brain diseases. Recent postmortem and imaging studies have in-dicated microglial activation in the brain of schizophrenia patients. Animal models that express some phenotypes of schizophrenia have revealed the underlying microglial pathology. In addition, minocycline, an antibiotic and the best known inhibitor of microglial activation, has therapeutic e‹cacy in schizophrenia. We have recently revealed that vari- ous antipsychotics directly affect microglia via proin‰ammatory reactions such as oxidative stress, by in vitro studies using rodent microglial cells. Based on these ˆndings, we have suggested that microglia are crucial players in the brain in schizophrenia, and modulating microglia may be a novel therapeutic target. In this review paper, we introduce our hypothesis based on the above evidence. The technique of in vivo molecular redox imaging is expected to be a powerful tool to clarify this hypothesis.",
author = "Kato, {Takahiro A.} and Fuminori Hyodo and Mayumi Yamato and Hideo Utsumi and Shigenobu Kanba",
year = "2015",
month = "1",
day = "1",
language = "English",
volume = "135",
pages = "739--743",
journal = "Yakugaku Zasshi",
issn = "0031-6903",
publisher = "公益社団法人 日本薬学会",
number = "5",

}

TY - JOUR

T1 - Redox and microglia in the pathophysiology of schizophrenia

AU - Kato, Takahiro A.

AU - Hyodo, Fuminori

AU - Yamato, Mayumi

AU - Utsumi, Hideo

AU - Kanba, Shigenobu

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Altered antioxidant status has been implicated in schizophrenia. Microglia are major sources of free radicals such as superoxide in the brain, and play crucial roles in various brain diseases. Recent postmortem and imaging studies have in-dicated microglial activation in the brain of schizophrenia patients. Animal models that express some phenotypes of schizophrenia have revealed the underlying microglial pathology. In addition, minocycline, an antibiotic and the best known inhibitor of microglial activation, has therapeutic e‹cacy in schizophrenia. We have recently revealed that vari- ous antipsychotics directly affect microglia via proin‰ammatory reactions such as oxidative stress, by in vitro studies using rodent microglial cells. Based on these ˆndings, we have suggested that microglia are crucial players in the brain in schizophrenia, and modulating microglia may be a novel therapeutic target. In this review paper, we introduce our hypothesis based on the above evidence. The technique of in vivo molecular redox imaging is expected to be a powerful tool to clarify this hypothesis.

AB - Altered antioxidant status has been implicated in schizophrenia. Microglia are major sources of free radicals such as superoxide in the brain, and play crucial roles in various brain diseases. Recent postmortem and imaging studies have in-dicated microglial activation in the brain of schizophrenia patients. Animal models that express some phenotypes of schizophrenia have revealed the underlying microglial pathology. In addition, minocycline, an antibiotic and the best known inhibitor of microglial activation, has therapeutic e‹cacy in schizophrenia. We have recently revealed that vari- ous antipsychotics directly affect microglia via proin‰ammatory reactions such as oxidative stress, by in vitro studies using rodent microglial cells. Based on these ˆndings, we have suggested that microglia are crucial players in the brain in schizophrenia, and modulating microglia may be a novel therapeutic target. In this review paper, we introduce our hypothesis based on the above evidence. The technique of in vivo molecular redox imaging is expected to be a powerful tool to clarify this hypothesis.

UR - http://www.scopus.com/inward/record.url?scp=84928950228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928950228&partnerID=8YFLogxK

M3 - Article

C2 - 25948311

AN - SCOPUS:84928950228

VL - 135

SP - 739

EP - 743

JO - Yakugaku Zasshi

JF - Yakugaku Zasshi

SN - 0031-6903

IS - 5

ER -